Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation

被引:61
作者
Valentini, G
Baroni, A
Esposito, K
Naclerio, C
Buommino, E
Farzati, A
Cuomo, G
Farzati, B
机构
[1] Univ Naples 2, Rheumatol Unit, Naples, Italy
[2] Univ Naples 2, Clin Microbiol Unit, Naples, Italy
[3] Secind Univ Naples, Immunohematol Unit, Naples, Italy
关键词
cytokines; systemic sclerosis; T lymphocytes;
D O I
10.1023/A:1011024313525
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Our objective was to investigate the phenotype of helper T cells in the peripheral blood of patients with systemic sclerosis (SSc). PBMC from 15 patients with SSc and 15 sex- and age-matched controls were investigated for lymphocyte subpopulations (CD3, CD4, CD8, CD19, CD16/CD56, CD3-DR); IL-2, LL-4, and IFN-gamma mRNAs; and the relative cytokines in their cytoplasm. The last assay was carried out both in unstimulated and in PMA-activated PBMC. SSc patients presented a higher percentage of activated T cells, CD3+ DR+ (19.7 +/- 9.9 vs 5.1 +/- 2.5%; P < 0.0001); 12 of them presented IFN-gamma mRNA-positive cells; and none IL-2 or IL-4 mRNAs. Under basal conditions, PBMC from six SSc patients contained IL-2, IL-4, and IFN-gamma (i.e., they showed both Th1 and Th2 activation), and 1 IFN-gamma only. PMA-stimulated PBMC of patients differed from those of controls only in the increased percentage of IFN-gamma positive cells (52 +/- 12 vs 37 +/- 11%; P < 0.01). Our study demonstrates that Thl activation occurs in the peripheral blood of SSc patients. This evidence must be faced with from both a pathogenetic and a therapeutical point of view.
引用
收藏
页码:210 / 217
页数:8
相关论文
共 41 条
[21]  
LEROY EC, 1996, CECIL TXB MED, P1483
[22]  
MAGGI E, 1991, J IMMUNOL, V146, P1169
[23]  
Mavilia C, 1997, AM J PATHOL, V151, P1751
[24]  
Molteni M, 1999, CLIN EXP IMMUNOL, V116, P164
[25]   DECREASED LYMPHOCYTE BLASTOGENESIS, IL2 PRODUCTION AND NK ACTIVITY FOLLOWING NIFEDIPINE ADMINISTRATION TO HEALTHY HUMANS [J].
MORGANO, A ;
PIERRI, I ;
STAGNARO, R ;
SETTI, M ;
PUPPO, F ;
INDIVERI, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :545-550
[26]   INTERLEUKIN-1, INTERLEUKIN-2, INTERLEUKIN-4, INTERLEUKIN-6, TUMOR-NECROSIS-FACTOR-ALPHA, AND INTERFERON-GAMMA LEVELS IN SERA FROM PATIENTS WITH SCLERODERMA [J].
NEEDLEMAN, BW ;
WIGLEY, FM ;
STAIR, RW .
ARTHRITIS AND RHEUMATISM, 1992, 35 (01) :67-72
[27]   SEQUENTIAL DERMAL MICROVASCULAR AND PERIVASCULAR CHANGES IN THE DEVELOPMENT OF SCLERODERMA [J].
PRESCOTT, RJ ;
FREEMONT, AJ ;
JONES, CJP ;
HOYLAND, J ;
FIELDING, P .
JOURNAL OF PATHOLOGY, 1992, 166 (03) :255-263
[28]  
PRIOR C, 1992, CLIN EXP IMMUNOL, V88, P280
[29]  
RAMBALDI PF, 1997, EUR J NUCL, V24, P1048
[30]  
Rotondo A, 1993, Radiol Med, V86, P213